Crucell was a biotechnology company focused on vaccine development. It addressed various infectious diseases through research and the creation of new vaccines. Its efforts contributed to advancements in public health by developing preventative measures against widespread illnesses.
The Rise of Crucell
Crucell originated from Introgene, a spin-off company established in 1993 from Leiden University in the Netherlands. Introgene initially focused on vector technology and viral-based products, forming partnerships with companies like Genzyme. This early work laid the foundation for its future in biotechnology. In 2000, Introgene acquired U-Bisys, a Dutch antibody developer, leading to the formation of Crucell. The company’s headquarters were located in Leiden, a notable biotechnology cluster in the Netherlands.
Crucell expanded its reach and capabilities by integrating other vaccine specialists. In 2006, it joined forces with Berna Biotech from Switzerland, SBL Vaccin from Sweden, and US-based Berna Products. These integrations positioned Crucell as one of the world’s larger vaccine companies, developing vaccines for infectious diseases such as influenza, malaria, and Ebola.
Pioneering Vaccine Development
A notable advancement was the development of Crucell’s PER.C6 cell line technology. This human cell line was designed to produce vaccines and antibodies more efficiently, offering a robust platform for biopharmaceutical manufacturing. The PER.C6 technology allowed for the scalable production of various vaccine candidates, including those for influenza and other viral diseases.
The company’s research pipeline included product candidates like flu-mAb, an antibody product effective against a broad range of influenza virus strains. Crucell also engaged in the development of vaccines for tuberculosis and malaria, as well as a rabies monoclonal antibody combination.
Crucell’s Integration and Enduring Impact
Crucell’s trajectory shifted with its acquisition by Johnson & Johnson. In September 2009, Johnson & Johnson initially purchased an 18% stake in Crucell for €302 million to collaborate on influenza vaccine development. This partnership followed Crucell’s discovery of CR6261, a potent human antibody capable of neutralizing a broad range of influenza A viruses. Johnson & Johnson completed the acquisition of the remaining shares by February 2011, taking its stake to over 95% and subsequently delisting Crucell from stock exchanges.
Following the takeover in 2011, Crucell was integrated into Johnson & Johnson’s Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed Janssen Vaccines, reflecting its new identity. The PER.C6 platform, a core technology developed by Crucell, continues to be utilized in current vaccine development efforts by Janssen Vaccines. This integration provided Johnson & Johnson with a stronger foothold in disease prevention, allowing Crucell’s legacy to endure and influence ongoing research and production in the vaccine field.